Production (Stage)
Lixte Biotechnology Holdings, Inc.
LIXT
$1.33
-$0.0502-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.13% | 29.51% | 29.65% | 34.37% | 22.12% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.71% | -45.89% | -57.85% | -66.42% | -59.61% |
| Change in Net Operating Assets | -112.44% | -85.44% | 175.31% | 657.58% | 191.04% |
| Cash from Operations | 22.76% | 26.29% | 24.60% | 28.46% | 21.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.88% | -- | -88.46% | 55,455.56% | -32.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -3,429.36% |
| Cash from Financing | -70.86% | -- | -100.00% | 49,695.24% | -39.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.13% | -175.20% | -138.15% | 93.41% | -317.00% |